In light of the poor prognosis for cervical cancer, research continues into the development of innovative and efficacious treatment modalities for this disease. We investigated the role of hepatocyte growth factor activator inhibitor-2 (HAI-2) and evaluated its clinical importance in cervical cancer.
Hepatocyte growth factor activator inhibitor-2 (HAI-2) is a favorable prognosis marker and inhibits cell growth through the apoptotic pathway in cervical cancer.
Department of Obstetrics and Gynecology, Okayama University Graduate School of Medical, Dentistry and Pharmaceutical Sciences, Okayama, Japan. k-nakamu@cc.okayama-u.ac.jp
